These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25529734)

  • 1. Development of constrained tamoxifen mimics and their antiproliferative properties against breast cancer cells.
    Archana S; Geesala R; Rao NB; Satpati S; Puroshottam G; Panasa A; Dixit A; Das A; Srivastava AK
    Bioorg Med Chem Lett; 2015 Feb; 25(3):680-4. PubMed ID: 25529734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents.
    Kaur G; Mahajan MP; Pandey MK; Singh P; Ramisetti SR; Sharma AK
    Eur J Med Chem; 2014 Oct; 86():211-8. PubMed ID: 25164760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of targeted dibenzo[b,f]thiepines and dibenzo[b,f]oxepines as potential lead molecules with promising anti-breast cancer activity.
    Ansari MI; Hussain MK; Arun A; Chakravarti B; Konwar R; Hajela K
    Eur J Med Chem; 2015 Jun; 99():113-24. PubMed ID: 26067208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of 2,2-dimethyl-chroman-based stereochemically flexible and constrained anti-breast cancer agents.
    Nainawat KS; Gupta K; Gupta N; Singh R; Mishra D; Nirwan A; Verma M; Singh A; Vasudev PG; Khan F; Mishra DP; Gupta A
    Bioorg Med Chem Lett; 2024 Aug; 108():129789. PubMed ID: 38729318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators.
    Shoda T; Kato M; Harada R; Fujisato T; Okuhira K; Demizu Y; Inoue H; Naito M; Kurihara M
    Bioorg Med Chem; 2015 Jul; 23(13):3091-6. PubMed ID: 26003343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique SERM-like properties of the novel fluorescent tamoxifen derivative FLTX1.
    Marrero-Alonso J; Morales A; García Marrero B; Boto A; Marín R; Cury D; Gómez T; Fernández-Pérez L; Lahoz F; Díaz M
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):898-910. PubMed ID: 23727370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
    Pigeon P; Top S; Vessières A; Huché M; Hillard EA; Salomon E; Jaouen G
    J Med Chem; 2005 Apr; 48(8):2814-21. PubMed ID: 15828819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P2Y2 receptor-mediated modulation of estrogen-induced proliferation of breast cancer cells.
    Li HJ; Wang LY; Qu HN; Yu LH; Burnstock G; Ni X; Xu M; Ma B
    Mol Cell Endocrinol; 2011 May; 338(1-2):28-37. PubMed ID: 21356271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, antiproliferative activity and estrogen receptor α affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues.
    Saha P; Descôteaux C; Brasseur K; Fortin S; Leblanc V; Parent S; Asselin E; Bérubé G
    Eur J Med Chem; 2012 Feb; 48():385-90. PubMed ID: 22209414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines.
    ter Haar E; Day BW
    Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and anti-breast cancer evaluation of new triarylethylene analogs bearing short alkyl- and polar amino-/amido-ethyl chains.
    Kaur G; Mahajan MP; Pandey MK; Singh P; Ramisetti SR; Sharma AK
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1963-9. PubMed ID: 26972118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
    Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
    Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, computational studies and antiproliferative activities of coumarin-tagged 1,3,4-oxadiazole conjugates against MDA-MB-231 and MCF-7 human breast cancer cells.
    Dhawan S; Kerru N; Awolade P; Singh-Pillay A; Saha ST; Kaur M; Jonnalagadda SB; Singh P
    Bioorg Med Chem; 2018 Nov; 26(21):5612-5623. PubMed ID: 30360952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient new constructs against triple negative breast cancer cells: synthesis and preliminary biological study of ferrocifen-SAHA hybrids and related species.
    Cázares Marinero Jde J; Lapierre M; Cavaillès V; Saint-Fort R; Vessières A; Top S; Jaouen G
    Dalton Trans; 2013 Nov; 42(43):15489-501. PubMed ID: 24030275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
    Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
    Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells.
    Yu HN; Noh EM; Lee YR; Roh SG; Song EK; Han MK; Lee YC; Shim IK; Lee SJ; Jung SH; Kim JS; Youn HJ
    Biochem Biophys Res Commun; 2008 Dec; 377(1):242-7. PubMed ID: 18835379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
    Toko T; Shibata J; Nukatsuka M; Yamada Y
    Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.